Do analysts recommend SIGA or AVLN?

Avalyn Pharma has a consensus price target of $59.00, indicating a potential upside of 96.14%. Given Avalyn Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Avalyn Pharma is more favorable than Siga Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Siga Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Avalyn Pharma 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.20

Which has stronger earnings & valuation, SIGA or AVLN?

Siga Technologies has higher revenue and earnings than Avalyn Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Siga Technologies $94.57M 3.28 $23.28M $0.27 16.00 Avalyn Pharma N/A N/A N/A N/A N/A

Do analysts recommend MPLT or SIGA?

Maplight Therapeutics presently has a consensus price target of $37.78, suggesting a potential upside of 36.14%. Given Maplight Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Maplight Therapeutics is more favorable than Siga Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maplight Therapeutics 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 3 Strong Buy rating(s) 3.00 Siga Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate IMTX or SIGA?

Immatics presently has a consensus price target of $20.80, indicating a potential upside of 121.75%. Given Immatics' stronger consensus rating and higher probable upside, research analysts clearly believe Immatics is more favorable than Siga Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immatics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63 Siga Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, IMTX or SIGA?

Siga Technologies has higher revenue and earnings than Immatics. Immatics is trading at a lower price-to-earnings ratio than Siga Technologies, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immatics $54.60M 23.03 -$222.26M -$1.99 N/A Siga Technologies $94.57M 3.28 $23.28M $0.27 16.00

Is IMTX or SIGA more profitable?

Siga Technologies has a net margin of 21.58% compared to Immatics' net margin of -572.35%. Siga Technologies' return on equity of 10.60% beat Immatics' return on equity. Company Net Margins Return on Equity Return on Assets Immatics -572.35% -47.36% -39.35% Siga Technologies 21.58% 10.60% 8.94%

Do analysts prefer COAG or SIGA?

Hemab Therapeutics currently has a consensus target price of $41.75, suggesting a potential upside of 67.13%. Given Hemab Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Hemab Therapeutics is more favorable than Siga Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hemab Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Siga Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, COAG or SIGA?

Siga Technologies has higher revenue and earnings than Hemab Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hemab Therapeutics N/A N/A N/A N/A N/A Siga Technologies $94.57M 3.28 $23.28M $0.27 16.00

Do analysts recommend SIGA or CALT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Siga Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Siga Technologies (SIGA) Competitors

$4.34 +0.02 (+0.35%)

As of 10:06 AM Eastern

Compare

SIGA vs. AVLN, MPLT, IMTX, COAG, and CALT

Should you buy Siga Technologies stock or one of its competitors? MarketBeat compares Siga Technologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Siga Technologies include Avalyn Pharma (AVLN), Maplight Therapeutics (MPLT), Immatics (IMTX), Hemab Therapeutics (COAG), and Calliditas Therapeutics AB (publ) (CALT). These companies are all part of the "pharmaceutical products" industry.

How does Siga Technologies compare to Avalyn Pharma?

Siga Technologies (NASDAQ:SIGA) and Avalyn Pharma (NASDAQ:AVLN) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

Siga Technologies has a net margin of 21.58% compared to Avalyn Pharma's net margin of 0.00%. Siga Technologies' return on equity of 10.60% beat Avalyn Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Siga Technologies	21.58%	10.60%	8.94%
Avalyn Pharma	N/A	N/A	N/A

55.4% of Siga Technologies shares are owned by institutional investors. 2.7% of Siga Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Avalyn Pharma had 1 more articles in the media than Siga Technologies. MarketBeat recorded 2 mentions for Avalyn Pharma and 1 mentions for Siga Technologies. Siga Technologies' average media sentiment score of 1.87 beat Avalyn Pharma's score of 0.43 indicating that Siga Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Siga Technologies	Very Positive
Avalyn Pharma	Neutral

Avalyn Pharma has a consensus price target of $59.00, indicating a potential upside of 96.14%. Given Avalyn Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Avalyn Pharma is more favorable than Siga Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Siga Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Avalyn Pharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.20

Siga Technologies has higher revenue and earnings than Avalyn Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Siga Technologies	$94.57M	3.28	$23.28M	$0.27	16.00
Avalyn Pharma	N/A	N/A	N/A	N/A	N/A

Summary

Siga Technologies beats Avalyn Pharma on 7 of the 12 factors compared between the two stocks.

How does Siga Technologies compare to Maplight Therapeutics?

Maplight Therapeutics (NASDAQ:MPLT) and Siga Technologies (NASDAQ:SIGA) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, media sentiment, institutional ownership, analyst recommendations and profitability.

Siga Technologies has higher revenue and earnings than Maplight Therapeutics. Maplight Therapeutics is trading at a lower price-to-earnings ratio than Siga Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A
Siga Technologies	$94.57M	3.28	$23.28M	$0.27	16.00

Maplight Therapeutics presently has a consensus price target of $37.78, suggesting a potential upside of 36.14%. Given Maplight Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Maplight Therapeutics is more favorable than Siga Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	3 Strong Buy rating(s)	3.00
Siga Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Maplight Therapeutics had 1 more articles in the media than Siga Technologies. MarketBeat recorded 2 mentions for Maplight Therapeutics and 1 mentions for Siga Technologies. Siga Technologies' average media sentiment score of 1.87 beat Maplight Therapeutics' score of 0.93 indicating that Siga Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Maplight Therapeutics	Positive
Siga Technologies	Very Positive

Siga Technologies has a net margin of 21.58% compared to Maplight Therapeutics' net margin of 0.00%. Siga Technologies' return on equity of 10.60% beat Maplight Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maplight Therapeutics	N/A	N/A	N/A
Siga Technologies	21.58%	10.60%	8.94%

55.4% of Siga Technologies shares are held by institutional investors. 3.8% of Maplight Therapeutics shares are held by insiders. Comparatively, 2.7% of Siga Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Siga Technologies beats Maplight Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Siga Technologies compare to Immatics?

Immatics (NASDAQ:IMTX) and Siga Technologies (NASDAQ:SIGA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.

Immatics presently has a consensus price target of $20.80, indicating a potential upside of 121.75%. Given Immatics' stronger consensus rating and higher probable upside, research analysts clearly believe Immatics is more favorable than Siga Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Siga Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Siga Technologies has higher revenue and earnings than Immatics. Immatics is trading at a lower price-to-earnings ratio than Siga Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immatics	$54.60M	23.03	-$222.26M	-$1.99	N/A
Siga Technologies	$94.57M	3.28	$23.28M	$0.27	16.00

64.4% of Immatics shares are held by institutional investors. Comparatively, 55.4% of Siga Technologies shares are held by institutional investors. 2.7% of Siga Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Immatics and Immatics both had 1 articles in the media. Siga Technologies' average media sentiment score of 1.87 beat Immatics' score of 0.93 indicating that Siga Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Immatics	Positive
Siga Technologies	Very Positive

Siga Technologies has a net margin of 21.58% compared to Immatics' net margin of -572.35%. Siga Technologies' return on equity of 10.60% beat Immatics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immatics	-572.35%	-47.36%	-39.35%
Siga Technologies	21.58%	10.60%	8.94%

Immatics has a beta of 1.3, indicating that its share price is 30% more volatile than the broader market. Comparatively, Siga Technologies has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market.

Summary

Siga Technologies beats Immatics on 9 of the 15 factors compared between the two stocks.

How does Siga Technologies compare to Hemab Therapeutics?

Hemab Therapeutics (NASDAQ:COAG) and Siga Technologies (NASDAQ:SIGA) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment.

In the previous week, Hemab Therapeutics had 1 more articles in the media than Siga Technologies. MarketBeat recorded 2 mentions for Hemab Therapeutics and 1 mentions for Siga Technologies. Siga Technologies' average media sentiment score of 1.87 beat Hemab Therapeutics' score of 0.93 indicating that Siga Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Hemab Therapeutics	Positive
Siga Technologies	Very Positive

Siga Technologies has higher revenue and earnings than Hemab Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemab Therapeutics	N/A	N/A	N/A	N/A	N/A
Siga Technologies	$94.57M	3.28	$23.28M	$0.27	16.00

Siga Technologies has a net margin of 21.58% compared to Hemab Therapeutics' net margin of 0.00%. Siga Technologies' return on equity of 10.60% beat Hemab Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hemab Therapeutics	N/A	N/A	N/A
Siga Technologies	21.58%	10.60%	8.94%

Hemab Therapeutics currently has a consensus target price of $41.75, suggesting a potential upside of 67.13%. Given Hemab Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Hemab Therapeutics is more favorable than Siga Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hemab Therapeutics	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Siga Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

55.4% of Siga Technologies shares are owned by institutional investors. 2.7% of Siga Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Siga Technologies beats Hemab Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Siga Technologies compare to Calliditas Therapeutics AB (publ)?

Siga Technologies (NASDAQ:SIGA) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Siga Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Siga Technologies has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market.

Siga Technologies has higher earnings, but lower revenue than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Siga Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Siga Technologies	$94.57M	3.28	$23.28M	$0.27	16.00
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A

In the previous week, Siga Technologies had 1 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 1 mentions for Siga Technologies and 0 mentions for Calliditas Therapeutics AB (publ). Siga Technologies' average media sentiment score of 1.87 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Siga Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Siga Technologies	Very Positive
Calliditas Therapeutics AB (publ)	Neutral

Siga Technologies has a net margin of 21.58% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Siga Technologies' return on equity of 10.60% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Siga Technologies	21.58%	10.60%	8.94%
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%

55.4% of Siga Technologies shares are held by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 2.7% of Siga Technologies shares are held by insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Siga Technologies beats Calliditas Therapeutics AB (publ) on 12 of the 14 factors compared between the two stocks.

Get Siga Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SIGA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SIGA vs. The Competition

Export

Metric	Siga Technologies	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$309.83M	$2.99B	$6.52B	$12.05B
Dividend Yield	N/A	1.76%	2.67%	5.66%
P/E Ratio	16.00	18.84	24.00	24.42
Price / Sales	3.28	455.32	533.77	123.88
Price / Cash	12.98	55.88	27.48	37.92
Price / Book	1.55	3.98	10.55	6.82
Net Income	$23.28M	$75.79M	$3.57B	$337.56M
7 Day Performance	-0.23%	1.57%	0.59%	1.16%
1 Month Performance	3.60%	-0.73%	1.55%	3.16%
1 Year Performance	-32.08%	23.44%	25.41%	30.60%

Siga Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SIGA Siga Technologies	0.5718 of 5 stars	$4.35 +0.6%	N/A	-32.1%	$311.62M	$94.57M	16.09	40	Positive News
AVLN Avalyn Pharma	4.8502 of 5 stars	$28.30 +0.9%	$59.00 +108.5%	N/A	$1.25B	N/A	N/A	51	Short Interest Increase Gap Down
MPLT Maplight Therapeutics	3.5151 of 5 stars	$29.17 -1.0%	$37.78 +29.5%	N/A	$1.24B	N/A	N/A	109	Gap Up
IMTX Immatics	2.8306 of 5 stars	$9.15 -0.8%	$20.80 +127.3%	+53.3%	$1.23B	$54.60M	N/A	260
COAG Hemab Therapeutics	4.5828 of 5 stars	$26.16 +2.4%	$41.75 +59.6%	N/A	$1.22B	N/A	N/A	72	Quiet Period Expiration

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SIGA) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Siga Technologies (SIGA) Competitors

SIGA vs. AVLN, MPLT, IMTX, COAG, and CALT

How does Siga Technologies compare to Avalyn Pharma?

Summary

How does Siga Technologies compare to Maplight Therapeutics?

Summary

How does Siga Technologies compare to Immatics?

Summary

How does Siga Technologies compare to Hemab Therapeutics?

Summary

How does Siga Technologies compare to Calliditas Therapeutics AB (publ)?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SIGA vs. The Competition

Siga Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Siga Technologies (SIGA) Competitors

SIGA vs. AVLN, MPLT, IMTX, COAG, and CALT

How does Siga Technologies compare to Avalyn Pharma?

Is SIGA or AVLN more profitable?

Do institutionals & insiders believe in SIGA or AVLN?

Does the media favor SIGA or AVLN?

Do analysts recommend SIGA or AVLN?

Which has stronger earnings & valuation, SIGA or AVLN?

Summary

How does Siga Technologies compare to Maplight Therapeutics?

Which has stronger valuation & earnings, MPLT or SIGA?

Do analysts recommend MPLT or SIGA?

Does the media prefer MPLT or SIGA?

Is MPLT or SIGA more profitable?

Do institutionals & insiders hold more shares of MPLT or SIGA?

Summary

How does Siga Technologies compare to Immatics?

Do analysts rate IMTX or SIGA?

Which has better valuation and earnings, IMTX or SIGA?

Do institutionals and insiders have more ownership in IMTX or SIGA?

Does the media refer more to IMTX or SIGA?

Is IMTX or SIGA more profitable?

Which has more risk and volatility, IMTX or SIGA?

Summary

How does Siga Technologies compare to Hemab Therapeutics?

Does the media prefer COAG or SIGA?

Which has preferable valuation & earnings, COAG or SIGA?

Is COAG or SIGA more profitable?

Do analysts prefer COAG or SIGA?

Do institutionals and insiders hold more shares of COAG or SIGA?

Summary

How does Siga Technologies compare to Calliditas Therapeutics AB (publ)?

Do analysts recommend SIGA or CALT?

Which has more risk and volatility, SIGA or CALT?

Which has preferable valuation and earnings, SIGA or CALT?

Does the media prefer SIGA or CALT?

Is SIGA or CALT more profitable?

Do insiders and institutionals hold more shares of SIGA or CALT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SIGA vs. The Competition

Siga Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools